UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway  

作　　者：Huhu Zhang Jiahua Yang Qinghang Song Xiaoyan Ding Fulin Sun Lina Yang 

机构地区：[1]Department of Genetics and Cell Biology,Basic Medical College,Qingdao University,Qingdao 266071,China [2]School of Basic Medicine,Qingdao University,Qingdao 266071,China [3]Institute of Brain Science and Disease,Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders,Qingdao University,Qingdao 266071,China [4]College of Medicine,Qingdao University,Qingdao 266071,China

出　　处：《Acta Biochimica et Biophysica Sinica》2024年第2期199-209,共11页生物化学与生物物理学报（英文版）

基　　金：This work was supported by the grants from the National Natural Science Foundation of China(No.81803895);Shandong Province Natural Science Foundation(No.ZR2021YQ57);China Postdoctoral Science Foundation(Nos.2020M682131 and 2021T140357).

摘　　要：Intrahepatic cholangiocarcinoma(icC)accounts for approximately 15%of primary liver cancers,and the incidence rate has been increasing in recentyears.Surgical resection is the best treatment for IcC,but the 5-year survival rate is less than 30%.IcC signature genes are crucial for the early diagnosis of IcC,so it is especially important to identify signature genes.The aim of this study is to screen the signature genes of IcC and find the potential target for the treatment of ICC.We find that UBA3 is highly expressed in ICC,and knockdown of UBA3 inhibits ICC proliferation,invasion and migration.Mechanistic experiments show that UBA3 promotes IcC proliferation,invasion and mi-gration by affecting ANXA2 through the MAPK signaling pathway.UBA3 is a target of bufalin,and bufalin targeting UBA3 inhibits ICC development and progression through the MAPK signaling pathway.In conclusion,our study shows that bufalin inhibits IcC by targeting UBA3,which has emerged as a new biomarker and potential therapeutic target forIcc.

关 键 词：intrahepatic cholangiocarcinoma UBA3 ANXA2 BUFALIN PROGNOSIS PROLIFERATION migration 

分 类 号：R735.7[医药卫生—肿瘤]